88 related articles for article (PubMed ID: 18431694)
21. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
[TBL] [Abstract][Full Text] [Related]
22. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
24. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
Prasad M; Narula G; Chinnaswamy G; Arora B; Shet T; Panjwani P; Sengar M; Laskar S; Khanna N; Banavali S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
[TBL] [Abstract][Full Text] [Related]
25. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
27. New strategies for the treatment of advanced-stage Hodgkin's lymphoma.
Diehl V; Engert A; Re D
Hematol Oncol Clin North Am; 2007 Oct; 21(5):897-914. PubMed ID: 17908627
[TBL] [Abstract][Full Text] [Related]
28. The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity.
Mathas S
Hematol Oncol Clin North Am; 2007 Oct; 21(5):787-804. PubMed ID: 17908620
[TBL] [Abstract][Full Text] [Related]
29. Nodular lymphocyte-predominant hodgkin lymphoma.
Tsai HK; Mauch PM
Semin Radiat Oncol; 2007 Jul; 17(3):184-9. PubMed ID: 17591565
[TBL] [Abstract][Full Text] [Related]
30. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Nogová L; Rudiger T; Engert A
Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
[TBL] [Abstract][Full Text] [Related]
31. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.
Hutchings M; Loft A; Hansen M; Ralfkiaer E; Specht L
Hematol Oncol; 2006 Sep; 24(3):146-50. PubMed ID: 16729353
[TBL] [Abstract][Full Text] [Related]
32. Splenic marginal zone lymphoma with micronodular T-cell rich B-cell lymphoma.
Wang SA; Olson N; Zukerberg L; Harris NL
Am J Surg Pathol; 2006 Jan; 30(1):128-32. PubMed ID: 16330953
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
Wirth A; Yuen K; Barton M; Roos D; Gogna K; Pratt G; Macleod C; Bydder S; Morgan G; Christie D
Cancer; 2005 Sep; 104(6):1221-9. PubMed ID: 16094666
[TBL] [Abstract][Full Text] [Related]
34. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
Nogová L; Reineke T; Eich HT; Josting A; Müller-Hermelink HK; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen MV; Müller RP; Diehl V; Engert A
Ann Oncol; 2005 Oct; 16(10):1683-7. PubMed ID: 16093276
[TBL] [Abstract][Full Text] [Related]
35. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
[TBL] [Abstract][Full Text] [Related]
36. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
[TBL] [Abstract][Full Text] [Related]
37. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z; Natkunam Y; Bair E; Tibshirani R; Warnke RA
Am J Surg Pathol; 2003 Oct; 27(10):1346-56. PubMed ID: 14508396
[TBL] [Abstract][Full Text] [Related]
38. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.
Boudová L; Torlakovic E; Delabie J; Reimer P; Pfistner B; Wiedenmann S; Diehl V; Müller-Hermelink HK; Rüdiger T
Blood; 2003 Nov; 102(10):3753-8. PubMed ID: 12881319
[TBL] [Abstract][Full Text] [Related]
39. Micronodular T-cell/histiocyte-rich large B-cell lymphoma of the spleen: histology, immunophenotype, and differential diagnosis.
Dogan A; Burke JS; Goteri G; Stitson RN; Wotherspoon AC; Isaacson PG
Am J Surg Pathol; 2003 Jul; 27(7):903-11. PubMed ID: 12826882
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
Ekstrand BC; Lucas JB; Horwitz SM; Fan Z; Breslin S; Hoppe RT; Natkunam Y; Bartlett NL; Horning SJ
Blood; 2003 Jun; 101(11):4285-9. PubMed ID: 12586628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]